Neoantigen Vaccines
**Note:** The following describes an area of investigational scientific research. BH Onco's cellular products are investigational, have not been approved by the U.S. FDA, and are not offered as a treatment for any disease.
Neoantigen Vaccines are an innovative approach in cancer immunotherapy that harnesses the unique mutations present in an individual’s tumor to create a highly personalized vaccine. Neoantigens are tumor-specific proteins resulting from genetic mutations, which are not found in normal cells. By identifying these unique neoantigens through genomic sequencing of a patient's tumor, researchers can develop a vaccine that targets these specific proteins. When administered, the vaccine stimulates the patient's immune system to recognize and attack cancer cells presenting these neoantigens, aiming for a precise and effective response with minimal impact on healthy tissues. This personalized strategy not only targets existing cancer cells but also potentially enhances long-term immunity against cancer recurrence. Currently, neoantigen vaccines are being evaluated in clinical trials for various cancers, and early results suggest they hold great promise for tailoring cancer treatment to the individual’s unique tumor profile, offering a new avenue for personalized cancer care.
Date:
November 29, 2022
Category:
